225 related articles for article (PubMed ID: 25015919)
1. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
Tarr TB; Lacomis D; Reddel SW; Liang M; Valdomir G; Frasso M; Wipf P; Meriney SD
J Physiol; 2014 Aug; 592(16):3687-96. PubMed ID: 25015919
[TBL] [Abstract][Full Text] [Related]
2. Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
Tarr TB; Wipf P; Meriney SD
Mol Neurobiol; 2015 Aug; 52(1):456-63. PubMed ID: 25195700
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.
Tarr TB; Malick W; Liang M; Valdomir G; Frasso M; Lacomis D; Reddel SW; Garcia-Ocano A; Wipf P; Meriney SD
J Neurosci; 2013 Jun; 33(25):10559-67. PubMed ID: 23785168
[TBL] [Abstract][Full Text] [Related]
4. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs.
Ojala KS; Ginebaugh SP; Wu M; Miller EW; Ortiz G; Covarrubias M; Meriney SD
J Biol Chem; 2021; 296():100302. PubMed ID: 33465376
[TBL] [Abstract][Full Text] [Related]
5. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions.
Giovannini F; Sher E; Webster R; Boot J; Lang B
Br J Pharmacol; 2002 Aug; 136(8):1135-45. PubMed ID: 12163346
[TBL] [Abstract][Full Text] [Related]
7. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
8. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
Mantegazza R
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
[No Abstract] [Full Text] [Related]
9. New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases.
Tarr TB; Valdomir G; Liang M; Wipf P; Meriney SD
Ann N Y Acad Sci; 2012 Dec; 1275():85-91. PubMed ID: 23278582
[TBL] [Abstract][Full Text] [Related]
10. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
11. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
Flink MT; Atchison WD
J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
[TBL] [Abstract][Full Text] [Related]
12. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
13. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
14. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
15. Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.
Oh SJ
Expert Rev Clin Immunol; 2019 Oct; 15(10):991-1007. PubMed ID: 31533480
[No Abstract] [Full Text] [Related]
16. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
17. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
18. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3,4-diaminopyridine at the murine neuromuscular junction.
Ng F; Lee DC; Schrumpf LA; Mazurek ME; Lee Lo V; Gill SK; Maselli RA
Muscle Nerve; 2017 Feb; 55(2):223-231. PubMed ID: 27251582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
